Scholar Rock prise Regulatory Affairs director away from Biogen
pharmafile | September 18, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Scholar Rock, biotech, drugs, pharma, pharmaceutical
Scholar Rock has announced that it has moved to appoint Heather Faulds as Vice President of Regulatory Affairs. Faulds joins Scholar Rock, a company currently focused on SRK-015, its lead candidate for Spinal Muscular Atrophy (SMA), from Biogen and her former position of Senior Director of Regulatory Affairs.
During her time at Biogen, Faulds was responsible for aiding in the expedited FDA approval of Spinraza, the first approved treatment for SMA, and, presumably, a big part of the reason Faulds was brought into the fold at Scholar Rock. Faulds will be tasked with managing the regulatory strategy for the company’s pipeline of drug candidates.
Faulds has 15 years of experience working in a regulatory capacity, including a number of years working through roles at Biogen – including, Senior Manager of Regulatory Affairs through to her former role as Senior Director within the same area.
“I am excited about Scholar Rock’s passionate team and inspiring vision for developing innovative medicines in areas of high unmet medical need,” said Faulds. “It was a privilege for me to contribute to the approval of the first drug product that has made such a meaningful difference in the lives of patients with SMA, and I look forward to building on that experience with the team at Scholar Rock to continue to bring SMA patients new therapeutic options.”
“I am delighted to welcome Heather to our team at this pivotal moment for Scholar Rock, as we plan and implement our regulatory strategy to advance SRK-015 into the clinic to address unmet needs for SMA patients,” said Nagesh Mahanthappa, President and Chief Executive Officer of Scholar Rock. “She brings key expertise, with a wide range of experience in regulatory affairs across all stages of development, from first-in-human studies to product approvals and product label expansions.”
The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …
On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …